Quince Therapeutics Inc
NASDAQ:QNCX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.5405
2.08
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one QNCX stock under the Base Case scenario is 1.43 USD. Compared to the current market price of 2.01 USD, Quince Therapeutics Inc is Overvalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Quince Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for QNCX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Quince Therapeutics Inc
Balance Sheet Decomposition
Quince Therapeutics Inc
Current Assets | 51.7m |
Cash & Short-Term Investments | 47.8m |
Other Current Assets | 3.9m |
Non-Current Assets | 74.8m |
Long-Term Investments | 78k |
PP&E | 767k |
Intangibles | 64.5m |
Other Non-Current Assets | 9.4m |
Current Liabilities | 5.4m |
Accounts Payable | 1.6m |
Accrued Liabilities | 3.8m |
Non-Current Liabilities | 76.2m |
Long-Term Debt | 14.9m |
Other Non-Current Liabilities | 61.3m |
Earnings Waterfall
Quince Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-38.1m
USD
|
Operating Income
|
-38.1m
USD
|
Other Expenses
|
-15.2m
USD
|
Net Income
|
-53.3m
USD
|
Free Cash Flow Analysis
Quince Therapeutics Inc
USD | |
Free Cash Flow | USD |
QNCX Profitability Score
Profitability Due Diligence
Quince Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Quince Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
QNCX Solvency Score
Solvency Due Diligence
Quince Therapeutics Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Quince Therapeutics Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
QNCX Price Targets Summary
Quince Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for QNCX is 9.18 USD with a low forecast of 6.06 USD and a high forecast of 12.6 USD.
Dividends
Current shareholder yield for QNCX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
QNCX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2019-05-09. The firm is focused on advancing precision therapeutics targeting debilitating and rare diseases. The firm has discovered a bone-targeting drug platform capable of delivering small molecules, peptides, or large molecules directly to the site of broad bone fractures and disease designed to promote more healing with fewer off-target safety concerns. The Company’s lead compound, NOV004, is an anabolic peptide engineered to target and concentrate at the bone fracture site. Its discovery pipeline is focused on expanding across multiple skeletal therapeutic indications, including osteogenesis imperfecta, fractures, spinal fusion, and other severe diseases of bone such as cancer or infection. The firm's pipeline also includes legacy neuroscience and antiviral programs available for out-licensing, which include COR588, COR388, COR852 and COR803.
Contact
IPO
Employees
Officers
The intrinsic value of one QNCX stock under the Base Case scenario is 1.43 USD.
Compared to the current market price of 2.01 USD, Quince Therapeutics Inc is Overvalued by 29%.